Zimbabwe has rejected a significant American healthcare agreement valued at $367m (£272m) spanning five years due to Washington's demand for sensitive biological samples.
This rejection became public after a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson later clarified that the United States was seeking health data for research and profit while was not willing to guarantee the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more dialogue to secure a deal agreeable to both sides so the nation's critical HIV programme can be sustained.
Wider Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a court blocked a similar health funding agreement following concerns were filed about the safety of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump argued its spending was "wasteful" and his government was pursuing government-to-government deals to boost openness and accountability.
Based on statements, Sixteen African countries have to date signed these new agreements, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data over an extended period, with no corresponding guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"Put simply, our country would provide the basic resources for scientific discovery with no assurance that the end products would be accessible to our population if a new disease outbreak arise."
National Interest and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining frameworks previously set up via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to manage potential pandemics.
"This system is designed to ensure that when a nation provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
These objections over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation could be designed in a way that respects the independence and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but recommended that negotiations should continue given that a large portion of the country's HIV programmes depended on foreign aid.
"If technical issues exist, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
This impasse emphasises the ongoing tensions between receiving vital international aid and safeguarding a country's data in an ever more interconnected world.